Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于海思科医药集团股份有限公司使用闲置自有资金进行委托理财的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from Huatai United Securities, acting as the sponsor institution, regarding the use of idle self-owned funds by Hisun Pharmaceutical Group Co., Ltd. for entrusted financial management. It includes investment purpose, amount, risk analysis, risk control measures, impact on the company, approval procedures, independent director opinions, and the sponsor's verification opinion. The document is regulatory in nature, focusing on compliance and procedural verification rather than presenting financial statements or earnings data. It does not contain financial results or detailed financial statements, nor is it a brief announcement or a presentation. It is a formal verification opinion related to a specific financial activity, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Management Reports. The document length is about 2400 characters, which is relatively short and more consistent with a regulatory filing or announcement rather than a full report.
2023-04-24 Chinese
独立董事关于第四届董事会第四十七次会议相关事项的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors regarding the pre-approval of the reappointment of an audit firm for the 2023 fiscal year. It references the audit work done for the 2022 annual financial statements and expresses an opinion on the audit firm's performance. The document is short (467 characters) and does not contain actual financial statements or detailed audit results, but rather an approval opinion related to audit matters. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related audit opinions, excluding full annual reports. It is not an announcement of a report publication, nor a certification letter, but an independent director's opinion on audit firm reappointment, which aligns with AR. FY 2022
2023-04-17 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 47th meeting of the 4th Board of Directors of 海思科医药集团股份有限公司. It includes approval of the 2022 annual general manager work report, 2022 financial report audited by an accounting firm, 2022 annual report and its summary, 2022 board work report, internal control self-evaluation report, and other governance matters such as reappointment of auditors, profit distribution plan, remuneration scheme, and use of idle raised funds. The document repeatedly references that the full 2022 annual report and related documents are published separately on the designated information disclosure media (巨潮资讯网). The document is relatively short (3029 characters) and serves as a formal board meeting resolution announcement rather than the full annual report itself. It does not contain the full financial statements or detailed financial data but refers to them being published elsewhere. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of board meeting resolutions and references the annual report rather than being the report itself.
2023-04-17 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2022 by 海思科医药集团股份有限公司. It discusses the company's internal control systems, evaluation of internal control effectiveness as of December 31, 2022, and the absence of significant deficiencies in financial and non-financial internal controls. The content is detailed and comprehensive, covering governance, organizational structure, audit, risk management, and internal control principles. It is not an announcement or a brief summary but a full report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, excluding full annual reports. The document length (9431 characters) and detailed content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-17 Chinese
海思科-未来三年（2023-2025年）股东回报规划
Regulatory Filings Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return policy for the next three years (2023-2025). It discusses profit distribution principles, forms of dividends (cash, stock), decision-making processes, and adjustment mechanisms. It references relevant laws and regulatory guidelines but does not contain financial statements or audit reports. The document is a policy or planning announcement rather than a financial report or earnings release. It is not a short announcement of a report publication but a substantive policy document. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about dividend policy and shareholder returns, not an actual dividend notice (DIV) or annual/interim report.
2023-04-17 Chinese
2022年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022 Annual Board of Directors Work Report" of 海思科医药集团股份有限公司. It details the board's activities, meetings, resolutions passed, and governance practices throughout the year 2022. It includes summaries of financial performance, board meeting frequency, committee activities, and outlook for 2023. The content is focused on the board's work and governance rather than full financial statements or audit results. The document length is 3677 characters, which is relatively short and consistent with a board work report rather than a full annual report or audit report. There is no indication that this is a presentation, call transcript, or announcement of voting results. The document is a detailed report on board activities and governance, fitting the category of Board/Management Information (MANG).
2023-04-17 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.